Lecanemab is approved for individuals with early stage Alzheimer’s disease, such as mild dementia or mild cognitive impairment, who have a biomarker-confirmed diagnosis.
The Clarity AD study, which UCLA participated in, showed individuals with early-stage Alzheimer’s disease who received Lecanemab for 18 months had substantially less amyloid protein in their brain and moderately less decline. Specifically, there was a 27% slower rate of progression as measured by the Clinical Dementia Rating scale, which quantifies symptom severity across a range of cognitive and functional domains. This translates to approximately five months of reduction in cognitive decline.
To learn more about Alzheimer’s disease treatment and care at UCLA, please speak with your primary care doctor or call the UCLA Amyloid Infusion Core at (310) 963-2592.
You can also visit our website to find a provider, schedule an appointment, and learn more about treatment and care options: www.uclahealth.org/medical-se...